Promotion: Capital invested is at risk. Non-Independent Research / Marketing Communication. Attention is drawn to the disclaimers and risk warnings within this document.
THIS ANNOUNCEMENT IS MADE FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE SHARES IN MEDPAL PLC IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL.
MedPal AI plc (AIM: MPAL), the AI-powered digital health company, is pleased to announce that MedPal Limited, its wholly owned subsidiary, has been approved as an authorised purchaser of Eli Lilly pharmaceutical products in the United Kingdom.
The approval enables the Company to purchase and dispense Eli Lilly's portfolio of medications, including those used for the treatment of type 2 diabetes and weight management.
Market Opportunity
The UK's leading weight loss medication, commands approximately 79% of the UK GLP-1 market and research indicates that approximately ten times more people in the UK purchase it privately than receive it through the NHS, highlighting the substantial commercial opportunity in the private prescribing market. Alternative GLP-1 receptor, which Medpal.clinic already supplies, represents 20% of the market. This approval means that it will now be able to offer GLP-1 patients their preferred medication.
The UK prescription weight loss medications market is forecast to grow from approximately £340 million in 2025 to £2 billion by 2033, driven by rising obesity prevalence and increasing adoption of GLP-1 therapies. An estimated 3.4 million people in the UK are eligible for this kind of treatment, with approximately 64% of adults in England classified as overweight or obese. Globally, the GLP-1 weight loss drugs market is projected to reach £120 billion by 2035. Direct supply access positions MedPal AI to serve the significant and growing private market demand through MedPal.clinic, where patients can access clinically supervised weight management pathways combining AI-powered triage with prescriber consultation.
Operational Capability
Medications will be dispensed from the Company's distribution centre in Swaffham, Norfolk, which utilises state-of-the-art robotic dispensing technology to ensure accuracy, efficiency and rapid fulfilment of patient orders. This automated infrastructure provides the scalability required to meet anticipated demand growth.
This development supports the Company's strategy to position MedPal.clinic as a leading digital platform for clinically supervised weight management services, combining AI-powered patient triage with access to innovative pharmaceutical treatments.
Jason Drummond, CEO of MedPal AI, commented:
"Securing direct supply rights with Eli Lilly, the manufacturer of the UK's leading weight loss medication, is an important milestone for MedPal AI. Access strengthens our ability to serve patients through MedPal.clinic, where our AI triage technology connects individuals with appropriate clinical pathways for weight management. With our robotic dispensing facility in Swaffham, we are well positioned to meet growing patient demand."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018). The Directors of the Company are responsible for the contents of this announcement.
Enquiries:
MedPal AI plc
Jason Drummond, Chief Executive Officer
Via Square1 Consulting
Cairn Financial Advisers LLP
Louise O'Driscoll/Jo Turner
+44 (0) 20 7213 0880
Clear Capital Markets Limited
Bob Roberts
+44 (0) 20 3869 6080
Square1 Consulting
David Bick
+44 (0) 20 7929 5599
+44 (0) 7831 381201
About MedPal AI
MedPal AI is a UK-based digital health company specialising in AI-driven wellness management. Its core app aggregates data from over 100 wearables and health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile, offering non-clinical, personalised lifestyle guidance through its AI wellness coach. The Company is also developing conversational AI to provide voice-based, real-time health insights, alerts, and recommendations.
Through its wholly owned subsidiary MedPal Limited, the Company operates a 24/7 AI-powered automated pharmacy distribution centre, providing nationwide NHS and private prescription services. The facility leverages advanced robotic dispensing technology integrated with AI triage to deliver rapid, cost-effective medication fulfilment with same-day and next-day delivery capabilities.
MedPal AI has a partnership agreement with Epassi UK Limited, which will, for a limited time, grant exclusive, zero-cost access to the MedPal AI app across Epassi's network of 11M+ employees at major firms like Siemens and Volvo. Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare providers, businesses, and insurers, with potential use in insurance-linked wellness programs to reduce premiums and drive new revenue through institutional partnerships. The Company also has a partnership agreement with Independent Gyms Ltd.
Forward Looking Statements
This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Source: https://www.londonstockexchange.com/news-article/MPAL/eli-lilly-supply-agreement/17433632
Nothing in the above article should be considered investment advice.
Small Cap or Aquis listed companies can be highly illiquid making them difficult to sell at the quoted price, and in some cases, it may be difficult to sell them at any price. Small Cap or Aquis listed companies can have a large bid / offer spread which means there could be a large difference between the buying and selling price. Companies listed on the Aquis market can be highly volatile and are considered high risk speculative investments. The value of your investment can go down as well as up, your Capital is at risk you may not get back the amount invested. Please ensure that you fully understand the risks involved. If in any doubt, please seek independent financial advice. This document is published by Clear Capital Markets and does not constitute a solicitation or personal recommendation for the purchase or sale of investment. The investments referred to may not be suitable for all investors. Any data or views given should not be construed as investment advice. Every effort is made to ensure the accuracy of the information, but no assurance or warranties are given.
Clear Capital Markets Corporate Broking acts as a Corporate Broker to MedPal PLC and holds warrants and shares in the company. Employees and/or directors of Clear Capital Markets may deal in shares of MedPal PLC for their own personal accounts. These scenarios may give rise to a conflict of interest where Clear Capital Markets also provides clients with an advisory service for transactions involving MedPal PLC. The firm has established Conflicts of Interest (“COI”) and Personal Account Dealing (“PAD”) policies to mitigate the risk of a conflict causing damage to the interests of its clients. The measures taken include (i) enforcing minimum holding or ‘lock-in’ periods; and (ii) requiring internal review and approval from the compliance department for employees or directors entering into personal transactions involving MedPal PLC. The COI and PAD policies are available upon request. Before Clear Capital Markets proceeds with a placing, a number of factors are considered including: liquidity of stock, company diversification, market capitalisation and potential news flow. Only once minimum criteria are satisfied would we elect to proceed. Any remuneration payable to Clear Capital Markets has no bearing on whether it proceeds with a placing. These administrative controls mitigate the risk of a conflict causing damage to the interest of a client, but the inherent risks of this business model cannot be eliminated. Accordingly, Clear Capital Markets is required to disclose this conflict to help clients to assess the service that they are being offered in light of Clear Capital’s own interests, and to decide on the extent (if at all) to which they will rely on, or proceed with, the service.
We will reach out for a quick introductory fact find to see how we can best serve your specific needs and arrange a convenient time for a consultation with a member of the appropriate specialist team.
An Advisory Broker will contact you for a deeper fact find and share information on how we can best enhance your portfolio.
We will conduct a full RCP in accordance with FCA regulations to ensure that your appropriate risk profile is set. You will then have access to an extensive suite of investments, supported by your dedicated Advisory Broker.
